tiprankstipranks
Trending News
More News >
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
US Market
Advertisement

Nurix Therapeutics (NRIX) AI Stock Analysis

Compare
455 Followers

Top Page

NRIX

Nurix Therapeutics

(NASDAQ:NRIX)

Rating:53Neutral
Price Target:
$11.50
▼(-1.12%Downside)
Nurix Therapeutics' score reflects its strong equity position and recent positive clinical trial results. However, ongoing profitability and cash flow challenges significantly impact its financial health, and bearish technical indicators further weigh down its overall score. The potential for future growth exists if the company can capitalize on its scientific advancements.
Positive Factors
Collaboration Revenue
Nurix reported $44.1M in collaboration/license revenue, exceeding previous estimates of $25.0M.
Investment Opportunity
Shares remain cheap, and offer an attractive entry point for long-term investors.
Pipeline Progress
Nurix plans to provide additional clinical updates for bexobrutideg and remains on track to initiate pivotal trials in CLL.
Negative Factors
Capital Overhang
There is a capital overhang that needs to be addressed for shares to work meaningfully higher.
Operating Expenses
Analyst slightly lowers the 12-month price target to $34 from $36 due to greater operating expenses.
Regulatory Uncertainty
The stock is not expected to perform well until there is clinical differentiation versus BGB-16673, clarity on a time- and capital-efficient development path, and/or a value-driving strategic partnership.

Nurix Therapeutics (NRIX) vs. SPDR S&P 500 ETF (SPY)

Nurix Therapeutics Business Overview & Revenue Model

Company DescriptionNurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
How the Company Makes MoneyNurix Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies. These agreements often include upfront payments, research funding, milestone payments, and potential royalties on sales of products developed through joint efforts. The company leverages its proprietary technology platform to engage in partnerships that enhance its drug discovery capabilities and expand its pipeline. Significant collaborations with leading pharmaceutical companies contribute to its earnings and support the ongoing research and development of its therapeutic candidates.

Nurix Therapeutics Financial Statement Overview

Summary
Nurix Therapeutics faces significant challenges in achieving profitability and sustainable cash flow. Despite a strong equity position with minimal leverage, the company struggles with negative net profit and cash flow margins, indicating ongoing operational difficulties.
Income Statement
45
Neutral
Nurix Therapeutics has shown an inconsistent revenue trend with notable fluctuations. The TTM data indicates a gross profit margin of 85.39%, reflecting efficient cost management relative to revenue. However, the company is struggling with profitability, as indicated by a negative net profit margin of -369.41%. EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges.
Balance Sheet
60
Neutral
The company displays a strong equity position, with an equity ratio of 78.19% in the TTM, indicating low leverage and a strong reliance on equity financing. However, the debt-to-equity ratio stands at 0.06, which is relatively low, suggesting minimal debt use. Return on Equity (ROE) remains negative due to ongoing net losses, impacting overall financial stability.
Cash Flow
50
Neutral
Operating cash flow is negative, reflecting ongoing cash burn from operations. The free cash flow growth rate remains concerning, with continued negative figures indicating challenges in generating cash from operations. However, the operating cash flow to net income ratio is slightly improving, suggesting potential operational efficiency gains.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue54.55M76.99M38.63M29.75M17.82M
Gross Profit38.12M-112.16M27.82M23.67M-48.67M
EBITDA-196.60M-141.41M-173.06M-111.80M-62.80M
Net Income-193.57M-143.95M-166.04M-117.19M-43.24M
Balance Sheet
Total Assets669.34M355.60M416.76M476.77M396.34M
Cash, Cash Equivalents and Short-Term Investments609.58M287.91M309.14M295.72M281.15M
Total Debt28.30M30.61M11.96M13.04M0.00
Total Liabilities142.35M155.10M113.06M134.47M106.07M
Stockholders Equity526.99M200.49M303.70M342.30M290.27M
Cash Flow
Free Cash Flow-181.86M-89.77M-172.05M-90.03M-4.63M
Operating Cash Flow-172.58M-81.36M-159.81M-84.36M-80.00K
Investing Cash Flow-257.71M68.30M27.20M-108.25M-254.40M
Financing Cash Flow485.67M3.22M117.19M153.88M339.02M

Nurix Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price11.63
Price Trends
50DMA
11.47
Positive
100DMA
11.63
Positive
200DMA
16.45
Negative
Market Momentum
MACD
-0.03
Positive
RSI
47.24
Neutral
STOCH
11.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Neutral. The current price of 11.63 is below the 20-day moving average (MA) of 12.05, above the 50-day MA of 11.47, and below the 200-day MA of 16.45, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 47.24 is Neutral, neither overbought nor oversold. The STOCH value of 11.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NRIX.

Nurix Therapeutics Risk Analysis

Nurix Therapeutics disclosed 81 risk factors in its most recent earnings report. Nurix Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Nurix Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$1.40B-57.92%-13.37%2.57%
57
Neutral
$553.27M-35.41%
55
Neutral
$969.91M-63.17%-40.51%-35.07%
53
Neutral
$860.06M-50.67%41.86%10.48%
53
Neutral
$867.48M-56.31%-106.10%
52
Neutral
$7.61B0.04-62.94%2.44%16.14%0.33%
49
Neutral
$1.05B-51.85%11070.12%32.07%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NRIX
Nurix Therapeutics
11.63
-9.41
-44.72%
IOVA
Iovance Biotherapeutics
3.97
-5.46
-57.90%
NTLA
Intellia Therapeutics
14.24
-12.18
-46.10%
RCUS
Arcus Biosciences
9.75
-5.23
-34.91%
ARVN
Arvinas Holding Company
7.87
-21.65
-73.34%
MLYS
Mineralys Therapeutics, Inc.
13.31
-0.16
-1.19%

Nurix Therapeutics Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Nurix Therapeutics Announces Positive Phase 1 Trial Results
Positive
Jun 12, 2025

On June 12, 2025, Nurix Therapeutics announced positive clinical data from its Phase 1 trial of bexobrutideg (NX-5948) at the European Hematology Association Congress. The data showed an objective response rate of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 84.2% in patients with Waldenström macroglobulinemia (WM), with bexobrutideg demonstrating a favorable safety profile and potential as a treatment for patients with high unmet medical needs. The company plans to initiate pivotal trials in 2025, reinforcing its scientific leadership in targeted protein degradation.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Nurix Therapeutics Holds 2025 Annual Stockholders Meeting
Neutral
May 19, 2025

On May 19, 2025, Nurix Therapeutics held its virtual 2025 Annual Meeting of Stockholders, where approximately 85.33% of the voting power was represented. Stockholders voted to elect three Class II directors, ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approve the compensation of named executive officers on a non-binding advisory basis.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025